使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Greetings and welcome to the Align Technology fourth-quarter and year-end 2015 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Shirley Stacy, VP Corporate and Investor Communications. Thank you, Ms. Stacy.
各位好,歡迎參加 Align Technology 2015 年第四季及全年財報電話會議。目前所有與會者皆處於僅收聽模式。正式簡報結束後將進行問答環節。(接線員指示) 提醒各位,本次會議將被錄音。現在我想將會議交給主持人——企業與投資人溝通副總裁 Shirley Stacy。謝謝您,Stacy 女士。
Shirley Stacy - VP, Corporate Communications and IR
Shirley Stacy - VP, Corporate Communications and IR
Good afternoon and thank you for joining us. I am Shirley Stacy, Vice President of Corporate Communications and Investor Relations. Joining me for today's call is Joe Hogan, President and CEO, and David White, CFO. We issued fourth-quarter and fiscal 2015 financial results today via Marketwire, which is available on our website at investor.aligntech.com. Today's conference call is being audio webcast and will be archived on our website for approximately 12 months. A telephone replay will be available today by approximately 5:30 PM Eastern time through 5:30 PM Eastern time on February 11. To access the telephone replay, domestic callers should dial 877-660-6853 with conference number 13627358 followed by #. International callers should dial 201-612-7415 with the same conference number.
各位下午好,感謝各位加入我們。我是 Shirley Stacy,企業傳播與投資人關係副總裁。今天與我一同出席電話會議的有總裁暨執行長 Joe Hogan,以及財務長 David White。我們已於今日透過 Marketwire 發布第四季及 2015 會計年度財務結果,並可於我們網站 investor.aligntech.com 查閱。今天的電話會議將以音訊網路直播,並會在我們網站上保存約 12 個月。電話重播將於今日美東時間約下午 5:30 起提供,至 2 月 11 日美東時間下午 5:30 止。如需收聽電話重播,美國境內來電者請撥 877-660-6853,輸入會議編號 13627358 後按 #;國際來電者請撥 201-612-7415,並輸入相同會議編號。
As a reminder, the information that the presenters discuss today will include forward-looking statements, including statements about Align's future events, product outlook and the expected financial results for the first quarter and full-year 2016. These forward-looking statements are only predictions and involve risks and uncertainties such that are set forth in more detail in our most recent periodic reports filed with the Securities and Exchange Commission. Actual results may vary significantly, and Align expressly assumes no obligation to update any forward-looking statements.
提醒各位,今天簡報者所討論的資訊將包含前瞻性陳述,包括關於 Align 未來事件、產品展望,以及 2016 年第一季與全年預期財務結果的陳述。這些前瞻性陳述僅為預測,並涉及風險與不確定性;相關內容已在我們最近向美國證券交易委員會提交的定期報告中更詳細說明。實際結果可能有重大差異,Align 明確表示不承擔更新任何前瞻性陳述之義務。
We have posted a set of GAAP and non-GAAP historical financial statements, including the corresponding reconciliations and our fourth-quarter conference call slides on our website under quarterly results. Please refer to these files for more detailed information.
我們已在網站「季度業績」專區發布一套 GAAP 與非 GAAP 歷史財務報表(含相應調節表),以及第四季電話會議簡報投影片。請參閱這些檔案以取得更詳細資訊。
With that, I will turn the call over to Align Technology's President and CEO, Joe Hogan. Joe?
接下來,我將把電話會議交給 Align Technology 總裁暨執行長 Joe Hogan。Joe?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thanks, Shirley. Good afternoon and thanks for joining us. On our call today, I will provide some financial highlights and then briefly discuss the performance of our two operating segments, Invisalign clear aligners and scanners. David will provide more detail on our financials and discuss our outlook for the first quarter, including some commentary on our view for 2016. Following that, I will come back and summarize a few key points and open up the call to questions.
謝謝,Shirley。各位下午好,感謝各位加入我們。在今天的電話會議中,我將先提供一些財務重點,接著簡要說明我們兩個營運部門——Invisalign 隱形矯正器與掃描儀——的表現。David 將更詳細說明我們的財務狀況,並討論第一季展望,包括對 2016 年看法的一些評論。之後我會再回來總結幾個關鍵重點,並開放提問。
Q4 was a strong finish to another record year for Align. Better than expected revenue and earnings were driven by record Invisalign volume, which is up 26% year over year. These results reflect strong growth across our customer base and geographies from both an increase in the number of submitters, as well as cases per doctor.
第四季為 Align 再創紀錄的一年畫下強勁句點。優於預期的營收與獲利主要由創紀錄的 Invisalign 出貨量所帶動,年增 26%。這些成果反映我們客戶基礎與各地區的強勁成長,成長動能同時來自提交病例的醫師數增加,以及每位醫師的病例數提升。
In addition, scanner revenue strong of 33% year over year exceeded expectations as shipments of our new iTero Element began ramping up this quarter, resulting in record scanner shipments. For the full year of 2015, over 500,000 patients started orthodontic treatment with Invisalign, an increase of 22% compared to 13% last year. Our increased growth reflects continued adoption and utilization from international doctors and a solid rebound in North America, both driven by investments in territory coverage and sales and marketing programs, including clinical education.
此外,掃描儀營收年增 33%,表現強勁且超出預期;本季我們新款 iTero Element 的出貨開始加速放量,帶動掃描儀出貨量創新高。2015 全年,超過 50 萬名患者以 Invisalign 開始正畸治療,較去年增加 22%(去年為 13%)。我們更高的成長反映國際醫師持續提高採用與使用率,以及北美市場的穩健回升;兩者皆受惠於我們在區域覆蓋、銷售與行銷方案(含臨床教育)上的投資。
Product and technology innovation is also a key growth driver for the Company, and as a result in 2015, we continue to see increased clinical confidence in Invisalign treatment for our customers worldwide.
產品與技術創新同樣是公司成長的關鍵驅動力,因此在 2015 年,我們持續看到全球客戶對 Invisalign 治療的臨床信心提升。
For Q4, North America clear aligner volume was both sequentially and year over year up, reflecting record Invisalign utilization and a record number of submitting doctors. Sequential growth was driven by North American GP dentists with an increase in both the number of submitters and cases per doctor.
就第四季而言,北美隱形矯正器出貨量不論較前一季或較去年同期皆成長,反映 Invisalign 使用量創新高,以及提交病例的醫師數創新高。季增主要由北美一般牙醫(GP)帶動,提交者數量與每位醫師病例數皆有所增加。
North American ortho volume also increased sequentially, although less so given Q4 is a seasonally slower for teenage orthodontic case starts. On a year-over-year basis, Q4 North America volume growth was driven by both orthos and GPs, reflecting increased utilization of Invisalign and expansion of our customer base.
北美正畸醫師(ortho)出貨量亦較前一季增加,但增幅較小,因第四季在青少年正畸病例啟動方面屬季節性較慢的季度。以年對年來看,第四季北美出貨量成長由正畸醫師與一般牙醫共同帶動,反映 Invisalign 使用率提升以及客戶基礎擴大。
For the full year, North America volume increased 18% compared to 8% last year and a three-year average of 12% reflecting the positive impact of our sales force expansion and go-to-market changes we announced on our earnings call last January.
全年而言,北美出貨量成長 18%,高於去年的 8%與三年平均的 12%,反映我們擴編銷售團隊以及去年 1 月在財報電話會議中宣布的市場進入策略調整所帶來的正面影響。
We are very pleased with the acceleration in growth rate and believe that we will see further progress in North America as we continue to drive greater adoption and utilization, and the ortho channel increased our share of the team market and improved patient conversion.
我們對成長率加速感到非常滿意,並相信隨著我們持續推動更高的採用與使用率、正畸通路提升在青少年市場的市占並改善患者轉換率,北美市場將會有進一步進展。
Q4 Invisalign volume for international doctors was up 17% sequentially and 35% year on year. Our international business continues to be very strong across all countries, driven by both an increase in the number of submitters and in cases per doctors in EMEA and continued expansion of our customer base in APAC.
第四季國際醫師的 Invisalign 出貨量較前一季成長 17%,較去年同期成長 35%。我們的國際業務在所有國家持續非常強勁,動能來自 EMEA 地區提交者數增加與每位醫師病例數提升,以及 APAC 地區客戶基礎持續擴張。
In EMEA, Q4 volume was up 34% year over year, and we had a record quarter across all markets. We continue to see strong performance in our five core country markets and are building momentum in our new geographies.
在 EMEA,第四季出貨量年增 34%,且我們在所有市場都創下單季紀錄。我們在五個核心國家市場持續展現強勁表現,並在新拓展地區建立成長動能。
For the full year 2015, EMEA volume growth of 30% was balanced across both ortho and GP channels. We also saw strong growth in Spain, the UK and the Mediterranean country markets, using our new selling process, which helps accelerate clinical confidence.
2015 全年,EMEA 出貨量成長 30%,在正畸與一般牙醫兩大通路間均衡分布。我們也在西班牙、英國與地中海國家市場看到強勁成長,並採用新的銷售流程以加速建立臨床信心。
In addition, newly integrated country markets previously indirect in the Nordics, Eastern Europe and Benelux are showing very good growth in their first full year of our direct focus. In Asia-Pacific, our Q4 volume reflected strong year-over-year growth of 37%, notwithstanding a seasonally slower period coming off a strong summer quarter.
此外,先前以間接模式經營、現已新整合納入的北歐、東歐與比荷盧國家市場,在我們直接投入的第一個完整年度即展現非常良好的成長。在亞太地區,儘管在強勁的夏季季度之後進入季節性較慢的期間,我們第四季出貨量仍呈現 37% 的強勁年對年成長。
During the quarter, we celebrated our 10th anniversary in Japan with a full day customer forum with over 200 Japanese doctors. We also participated in the China Annual Orthodontic Society meeting with nearly 400 doctors, and in December we attended our first Indian orthodontic congress in India where we are beginning to invest in trained orthodontists in a three key cities: Mumbai, New Delhi and Pune.
本季我們在日本慶祝 10 週年,舉辦一整天的客戶論壇,超過 200 位日本醫師參與。我們也參加了中國年度正畸學會會議,近 400 位醫師出席;並於 12 月首次參加印度的正畸大會。我們正開始在三個重點城市——孟買、新德里與浦那——投資培訓正畸醫師。
For the full year, clear aligner volume in APAC increased by 39%, reflecting both expansion of our customer base, as well as an increased utilization.
全年而言,APAC 的隱形矯正器出貨量成長 39%,反映客戶基礎擴張以及使用率提升。
In China, Invisalign volumes doubled over the prior year, and Japan grew more than 50% for the third consecutive year.
在中國,Invisalign 出貨量較前一年翻倍;而日本則連續第三年成長超過 50%。
In the important teen segment, the total number of Invisalign cases worldwide in Q4 increased 24% year over year. This reflects continued adoption across our customer channels, but more pronounced in North America where we have the greatest sales and marketing focus on teens.
在重要的青少年族群方面,第四季全球 Invisalign 青少年病例總數年增 24%。這反映我們各客戶通路持續採用,其中以北美最為明顯,因我們在青少年族群的銷售與行銷投入最為集中。
For the full year, over 141,000 teenagers started treatment with Invisalign, reflecting 21% growth compared to 16% growth in 2014. In North America, the growth rate of our teenage cases continues to outpace adult cases.
就全年而言,超過 141,000 名青少年開始接受 Invisalign 治療,較 2014 年 16% 的成長率提升至 21% 的成長。在北美,我們青少年病例的成長率持續超越成人病例。
Our integrated consumer marketing campaigns in North America, EMEA and APAC combine traditional paid media, search, digital marketing, PR and social media to engage customers at every point in the consumer purchasing journey. Consumer interest in demand for Invisalign treatment continues to grow as we can see from increases in key program metrics worldwide. For example, social media engagement and lead generation increased across all regions in 2015, and more than 8 million consumers visited one of our Invisalign consumer websites and almost 1.3 million of those visitors searched for an Invisalign provider on our site, up nicely from the prior year.
我們在北美、EMEA 與 APAC 的整合式消費者行銷活動,結合傳統付費媒體、搜尋、數位行銷、公關與社群媒體,在消費者購買旅程的每個接觸點與客戶互動。從全球關鍵計畫指標的提升可見,消費者對 Invisalign 治療的需求興趣持續成長。例如,2015 年各區域的社群媒體互動與潛在客戶開發皆有所增加;超過 800 萬名消費者造訪我們的 Invisalign 消費者網站,其中近 130 萬名訪客在我們網站上搜尋 Invisalign 供應醫師,較前一年明顯成長。
In Q4, our scanner sales and services business revenues were up 74% sequentially and up 33% year over year due to the introduction of our new iTero Element scanner, which has been received very enthusiastically by our customers. For Q4, total Invisalign cases submitted with digital scanners in North America were flat from last quarter at 40%. We believe due in part to fewer scanner sales in Q3 as we transition to our new iTero Element scanner.
在第四季,由於推出全新的 iTero Element 掃描器且獲客戶熱烈回響,我們的掃描器銷售與服務業務營收較前一季成長 74%,較去年同期成長 33%。第四季北美以數位掃描器提交的 Invisalign 總病例占比為 40%,與上一季持平。我們認為部分原因在於第三季於轉換至新的 iTero Element 掃描器期間,掃描器銷售較少。
While we are talking about our scanner business, I want to mention someone who has been an important part of the iTero's growth and success. Tim Mack, Vice President Scanner and Services, will be retiring in March after 25 years in the medical device industry. Tim joined the management team at Align when we acquired Cadent, and he has been instrumental in integrating the scanner business into the Company and bringing new innovations to market like iTero Element scanner.
既然談到掃描器業務,我想提到一位對 iTero 成長與成功至關重要的人。掃描器與服務事業部副總裁 Tim Mack 將於三月退休,他在醫療器材產業服務已 25 年。我們收購 Cadent 時 Tim 加入 Align 管理團隊;他在將掃描器業務整合進公司,以及將 iTero Element 掃描器等新創新推向市場方面,扮演了關鍵角色。
Over the next two months, Tim will transition his responsibility for our scanner and services business to Raph Pascaud, the Chief Marketing Portfolio and Business Development Officer, who will assume the role of General Manager for our scanner business. We are going to miss Tim, but I know he is going to enjoy having a personal life again after some very busy years.
在接下來兩個月,Tim 將把掃描器與服務業務的職責移交給首席行銷產品組合與業務發展長 Raph Pascaud;Raph 將出任掃描器業務的總經理。我們會想念 Tim,但我知道在這些非常忙碌的年頭之後,他將會享受重新擁有個人生活。
Now I will turn it over to David.
接下來我把時間交給 David。
David White - CFO
David White - CFO
Thanks, Joe. Let's review our fourth-quarter financial results.
謝謝你,Joe。我們來回顧第四季的財務結果。
Revenue for the fourth quarter was $230.3 million, up 10.9% from the prior quarter and up 15.9% from the corresponding quarter a year ago. On a year-over-year comparative basis, our fourth-quarter revenue growth rate was lower by approximately 8 points related to the additional aligner policy we implemented last July and the impact of foreign exchange rates.
第四季營收為 2.303 億美元,較前一季成長 10.9%,較去年同期成長 15.9%。以年對年比較而言,第四季營收成長率約低 8 個百分點,主要與我們去年七月實施的額外牙套政策,以及外匯匯率影響有關。
Fourth-quarter clear aligner revenue of $214.0 million was up 7.9% sequentially and up 14.8% year over year. The sequential revenue increase was primarily related to increased clear aligner volumes.
第四季透明牙套營收為 2.140 億美元,較前一季成長 7.9%,較去年同期成長 14.8%。營收的季增主要與透明牙套出貨量增加有關。
Q4 ASPs were slightly down, slightly sequentially, about $5, due to foreign exchange rates, as well as a small shift in product mix towards our low-end products. Our year-over-year revenue growth reflected Invisalign case volume growth across all customer channels and geographies, partially offset by lower ASPs, primarily to the additional aligner policy change and foreign currency exchange rates.
第四季 ASP(平均銷售單價)較前一季小幅下降,約 5 美元,原因包括外匯匯率,以及產品組合略微轉向我們的入門級產品。年對年營收成長反映 Invisalign 病例量在所有客戶通路與地區皆成長,但部分被 ASP 較低所抵銷;ASP 下滑主要源於額外牙套政策變更與外幣匯率。
For the fourth quarter, total Invisalign shipments of 160.4 thousand cases were up 8.8% sequentially, reflecting growth from our international North American customers. Year-over-year case volume growth was 26.4%, driven by growth across all regions.
第四季 Invisalign 總出貨量為 16.04 萬例,較前一季成長 8.8%,反映來自我們國際與北美客戶的成長。年對年病例量成長 26.4%,由各區域成長所帶動。
For North America orthodontists, Q4 Invisalign case volume was up 1.5% sequentially, reflecting higher adoption and utilization rates across the channel, and up 24.5% year over year.
就北美矯正專科醫師而言,第四季 Invisalign 病例量較前一季成長 1.5%,反映該通路的採用率與使用率提升;較去年同期成長 24.5%。
For North American GP dentists, case volume increased 9.4% sequentially and was up 20.3% year over year. For international doctors, Invisalign case volume was up 16.8% sequentially and 34.8% year over year.
就北美一般牙醫(GP)而言,病例量較前一季增加 9.4%,較去年同期成長 20.3%。就國際醫師而言,Invisalign 病例量較前一季成長 16.8%,較去年同期成長 34.8%。
Worldwide Invisalign utilization in Q4 was a record 4.9 cases per doctor, up from 4.4% in Q4 last year. North America ortho utilization was 9.9, up from 8.6 in the prior year. North America GP utilization was a record 3.1, up from 2.9 in the prior year, and international utilization was also a record at 5.0, up from 4.5 cases per doctor in Q4 last year.
第四季全球 Invisalign 使用率創新高,達每位醫師 4.9 例,高於去年第四季的 4.4。北美矯正專科使用率為 9.9,高於前一年的 8.6。北美一般牙醫使用率亦創新高,達 3.1,高於前一年的 2.9;國際使用率同樣創新高,達 5.0,高於去年第四季每位醫師 4.5 例。
For the full year 2015, we achieved record Invisalign utilization across all three customer channels.
2015 全年,我們在三大客戶通路的 Invisalign 使用率皆創下新高。
In Q4, we added 2670 new Invisalign doctors worldwide, 1270 of which were new North American doctors and 1400 of which were new international doctors. This is consistent with the same quarter a year ago.
第四季我們在全球新增 2,670 位 Invisalign 醫師,其中 1,270 位為新增北美醫師,1,400 位為新增國際醫師。這與去年同期一致。
For the full year, an additional 9795 doctors became Invisalign providers, reflecting continued expansion of our customer base, especially outside the US.
就全年而言,另有 9,795 位醫師成為 Invisalign 供應醫師,反映我們客戶基礎持續擴張,尤其是在美國以外地區。
Our scanner and services revenues for the fourth quarter were $16.2 million, up 73.7% sequentially and 33.4% year over year. We are excited to be ramping up production and shipping the new iTero Element scanners to our customer practices, given the high volume of preorders we have received since its announcement in March.
第四季掃描器與服務營收為 1,620 萬美元,較前一季成長 73.7%,較去年同期成長 33.4%。鑑於自三月發布以來收到大量預購訂單,我們很高興正加速提升產能,並將新的 iTero Element 掃描器出貨至客戶診所。
Moving on to gross margin. Fourth-quarter overall gross margin was 75.0%, down 0.9 points both sequentially and year over year. The year-over-year decrease in gross margin was primarily the result of lower ASPs from currency, which amounted to approximately 0.9 points, as well as the additional aligner policy change by about 0.7 points, which was partially offset by lower costs per unit.
接著談毛利率。第四季整體毛利率為 75.0%,較前一季與去年同期各下降 0.9 個百分點。年對年毛利率下降主要因匯率導致 ASP 較低,約影響 0.9 個百分點,以及額外牙套政策變更約影響 0.7 個百分點;部分被單位成本下降所抵銷。
Clear aligner gross margin for the fourth quarter was 77.9%, also down 0.9 points, both sequentially and year over year. The sequential decrease was primarily driven by higher freight costs and increased trading activity, which carries a lower margin.
第四季透明牙套毛利率為 77.9%,同樣較前一季與去年同期各下降 0.9 個百分點。季減主要由較高的運費成本與交易活動增加所致,而交易活動的毛利率較低。
Q4 gross margin for our scanner segment was 37.7%, up 23 points sequentially as a result of higher scanner ASPs and lower manufacturing costs associated with the new iTero Element. On a year-over-year basis, Q4 gross margin was up 7.5% as a result of product mix shift to the lower-cost iTero Element, coupled with reduced service costs.
第四季掃描器部門毛利率為 37.7%,因掃描器 ASP 較高以及新 iTero Element 相關製造成本較低,較前一季提升 23 個百分點。以年對年而言,第四季毛利率提升 7.5%,原因是產品組合轉向成本較低的 iTero Element,加上服務成本降低。
Q4 operating expenses were $113.5 million, down sequentially by $6.1 million, primarily due to lower marketing and media spend. Recall also that in Q3 we incurred severance costs for organizational changes, as well as costs related to the termination of product development efforts targeted for the obstructive sleep apnea market, which contributed to the sequential decline as well.
第四季營業費用為 1.135 億美元,較前一季減少 610 萬美元,主要因行銷與媒體支出降低。也請回想第三季我們因組織調整產生資遣費用,以及終止針對阻塞型睡眠呼吸中止症市場之產品開發投入所產生的相關成本,這些也促成了營業費用的季減。
On a year-over-year basis, Q4 operating expenses were up $14.3 million, or 14.4%, as a result of our sales expansion efforts, as well as our European implementation project.
以年對年而言,第四季營業費用增加 1,430 萬美元(或 14.4%),主要由我們的銷售擴張努力以及歐洲導入專案所致。
Our fourth-quarter operating margin was 25.8%, up 7.5 points sequentially and approximately flat year over year. The sequential increase in operating margin relates primarily to increased clear aligner volume and lower expenses. On a year-over-year basis, Q4 operating margin was impacted by approximately 3 points from foreign currency and the additional aligner policy.
我們第四季的營業利益率為25.8%,較前一季上升7.5個百分點,且與去年同期大致持平。營業利益率的季增主要與透明矯正器出貨量增加及費用降低有關。以年對年來看,第四季營業利益率約受到外幣匯率及新增矯正器政策合計約3個百分點的影響。
With regards to our fourth-quarter tax provision, our tax rate of 18.1% was down 6.3 points from our Q3 tax rate. This was primarily the result of a more favorable mix of earnings and lower tax geographies, lower tax expenses realized upon the filing of certain tax returns, and, to a lesser extent, the renewal of the US R&D tax credit. These items together amounted to about an incremental $0.04 benefit in earnings per share in the quarter.
關於我們第四季的所得稅提列,我們的稅率為18.1%,較第三季稅率下降6.3個百分點。這主要是由於獲利組合更有利且更多來自低稅負地區、在申報部分稅表時實現較低的稅務費用,以及在較小程度上,美國研發(R&D)稅額抵減的續期所致。上述項目合計使本季每股盈餘約增加0.04美元的增量利益。
Fourth-quarter diluted earnings per share was $0.60 compared to $0.34 reported in Q3 and $0.48 reported in the same quarter last year. Fourth-quarter EPS was impacted by approximately $0.07 related to the Company's new additional aligners policy.
第四季稀釋後每股盈餘為0.60美元,相較第三季報告的0.34美元,以及去年同期報告的0.48美元。第四季每股盈餘約受到公司新的新增矯正器政策相關影響0.07美元。
Finally, the year-over-year impact on the fourth quarter from the additional aligner policy change, as well as assuming constant year-over-year foreign currency exchange rates, was approximately $0.11 per share.
最後,新增矯正器政策變更對第四季的年對年影響,加上假設年對年外幣匯率維持不變,合計約為每股0.11美元。
Moving to the balance sheet. Capital expenditures for the fourth quarter were $16.8 million, primarily relating to equipment purchases to expand our manufacturing capacity in Juarez, Mexico, as well as our ERP implementation. Cash flow from operations for the fourth quarter was $79.4 million, and free cash flow for the fourth quarter, defined as cash flow from operations, less capital expenditures, amounted to $62.6 million.
接著看資產負債表。第四季資本支出為1,680萬美元,主要與購置設備以擴增我們在墨西哥華雷斯(Juarez)的製造產能,以及我們的ERP導入相關。第四季營運活動現金流為7,940萬美元;第四季自由現金流(定義為營運活動現金流減資本支出)為6,260萬美元。
During the fourth quarter, we repurchased 179,000 shares of stock, amounting to $11.2 million in open market repurchases.
第四季期間,我們回購了17.9萬股股票,公開市場回購金額合計1,120萬美元。
As a side note, our last 12 months of stock repurchases, together with cash used to pay employee taxes for the net settlement of investing employee stock awards that otherwise would have been issued, amounted to 66% of our worldwide free cash flow. We believe our free cash flow generation and these repurchases are consistent with our express capital allocation objectives returning cash flow in excess of that needed to run and grow the business to our shareholders.
補充說明,我們過去12個月的股票回購,加上用於支付員工稅款(針對投資型員工股票獎酬以淨額交割、原本將發行的股份)的現金支出,合計相當於我們全球自由現金流的66%。我們認為,我們的自由現金流創造能力以及這些回購,符合我們明確的資本配置目標:將超出營運與成長所需的現金流回饋給股東。
Cash, cash equivalents and marketable securities, including both short- and long-term investments, were $679 million. This compared to $603 million at the end of 2014, an increase of approximately $76 million.
現金、約當現金及有價證券(包含短期與長期投資)為6.79億美元。相較於2014年底的6.03億美元,約增加7,600萬美元。
Of our $670 million of cash, cash equivalents, and marketable securities, $236 million was held by the US, and $443 million was held by our international entities.
在我們6.70億美元的現金、約當現金及有價證券中,2.36億美元由美國持有,4.43億美元由我們的海外實體持有。
Before we move to the Q1 outlook, I would like to make a few comments on our full year 2015 results. In 2015, we shipped a record 583.2 thousand Invisalign cases, up 22%. This reflects 32.5% volume growth from international doctors and 17.7% volume growth from our North American doctors. Revenue was a record $845.5 million, up 11% year over year, including the impact of foreign exchange and the additional aligners policy. Full-year operating income of $188.6 million, or 22.3% of revenue, which included 1.6 points of impact from additional aligners and foreign exchange rates on a constant currency basis. Our operating results also included approximately $12 million of costs related to ERP and a one-time refund of $6.8 million for medical device excise tax refund, which will not recur in 2016.
在我們進入第一季展望之前,我想先就2015年全年結果做幾點說明。2015年,我們出貨創紀錄的58.32萬件Invisalign病例(cases),成長22%。其中反映海外醫師端出貨量成長32.5%,以及北美醫師端出貨量成長17.7%。營收創紀錄達8.455億美元,年增11%,其中包含外匯與新增矯正器政策的影響。全年營業利益為1.886億美元,約占營收22.3%;以固定匯率基礎計算,其中包含新增矯正器與外匯匯率合計1.6個百分點的影響。我們的營運結果亦包含約1,200萬美元與ERP相關的成本,以及一次性的6.80百萬美元醫療器材消費稅退稅,該項將不會在2016年重複發生。
Free cash flow was $184.5 million or 22% of revenue, consistent with our long-term model target of 20% to 25%. For the year, we repurchased 1.7 million shares of Align stock for $101.8 million. 2015 diluted EPS was $1.77.
自由現金流為1.845億美元,約占營收22%,符合我們長期模型目標的20%至25%。全年我們回購了170萬股Align股票,金額為1.018億美元。2015年稀釋後每股盈餘為1.77美元。
To recap, 2015 was a strong year for Align, and despite several headwinds, including foreign exchange rates, as well as the impact of our new policy -- additional aligner policy, we did better than planned across the board. Strong Invisalign growth offset much of these headwinds, enabled us to achieve revenue growth in operating margins above our original outlook.
總結而言,2015年對Align而言是強勁的一年;儘管面臨多項逆風,包括外匯匯率,以及我們新政策——新增矯正器政策——的影響,我們整體表現仍優於原先規劃。Invisalign的強勁成長抵消了多數逆風,使我們得以達成營收成長,且營業利益率高於原先展望。
With that, let's now turn to our business outlook for the first quarter and the factors that inform our view. Starting with the demand outlook. Consistent with current demand trends, we expect North America volume to be up sequentially in Q1, primarily driven by the ortho channel. For our international business, while we expect continued strong year-over-year growth, Q1 is a seasonally slower period in Europe due to winter holidays, and notwithstanding sequential growth expected from APAC, we anticipate total international volume to be down sequentially.
接下來,我們轉向第一季的業務展望以及支撐我們觀點的因素。先從需求展望談起。依循目前需求趨勢,我們預期北美第一季出貨量將較前一季增加,主要由齒顎矯正(ortho)通路帶動。至於國際業務,雖然我們預期年對年仍將維持強勁成長,但第一季在歐洲因冬季假期屬季節性較慢的期間;即便預期亞太(APAC)將帶來季增,我們仍預估整體國際出貨量將較前一季下降。
As for our scanner business, demand for our new iTero Element scanner has been strong. As a result, we expect Q1 scanner shipments to be up significantly sequentially. With this as a backdrop, we expect the first quarter to shape up as follows. Invisalign case volume is anticipated to be in the range of 161.3 thousand to 163.7 thousand cases, up approximately 23.4% to 25.2% over the same period a year ago. We expect Q1 net revenues to be in the range of $232.5 million to $236.6 million. We expect Q1 gross margin to be in the range of 73.5% to 74.1%, slightly down sequentially, primarily due to a higher mix of our scanner business which carries lower gross margins. We expect Q1 operating expenses to be in the range of $130.9 million to $132.4 million.
至於我們的掃描儀業務,新款iTero Element掃描儀的需求一直很強勁。因此,我們預期第一季掃描儀出貨量將較前一季大幅增加。在此背景下,我們預期第一季表現如下。Invisalign病例量預計介於16.13萬至16.37萬件,較去年同期約成長23.4%至25.2%。我們預期第一季淨營收介於2.325億至2.366億美元。我們預期第一季毛利率介於73.5%至74.1%,較前一季略降,主要因掃描儀業務占比提高,而該業務毛利率較低。我們預期第一季營業費用介於1.309億至1.324億美元。
Typical of prior years, Q1 operating expenses will increase quarter over quarter, based on several factors. First of all, employee compensation related costs will increase in Q1 due to our annual cycle of employee compensation reviews, which include salary increases and promotions, as well as annual stock grants and employer paid payroll taxes such as Social Security taxes in the US that we had set with the start of each new calendar year.
如同往年,第一季營業費用將較上一季增加,原因有數項。首先,第一季與員工薪酬相關的成本將上升,因為我們每年會進行員工薪酬檢視週期,包含加薪與升遷,以及年度股票授予與雇主負擔的薪資稅(例如美國的社會安全稅),這些通常在每個新曆年開始時重設。
Second, incremental investments and sales territory coverage, go to market and product development activities will increase operating expenses as we add additional resources, much of which is front-end loaded in the year.
第二,隨著我們增加額外資源,對銷售區域覆蓋、上市推廣(go to market)以及產品開發活動的增量投資將提高營業費用,其中多數在年度前期投入。
And, finally, we are entering the last stages of our European implementation program and will not be able to capitalize as much of our total program costs as compared to the earlier stages of the program. Our Q1 operating margin should be in the range of 17.2% to 18.2%. On a quarter over quarter basis, this is relatively consistent with historical Q4 to Q1 trends if you exclude ERP investments and the impact from a higher mix of our scanner business.
最後,我們正進入歐洲導入計畫的最後階段,與計畫早期階段相比,我們將無法將同等比例的總計畫成本資本化。我們第一季營業利益率應介於17.2%至18.2%。以季對季來看,若排除ERP投資以及掃描儀業務占比提高的影響,這與歷史上第四季到第一季的趨勢相對一致。
Our effective tax rate should be approximately 25%, and diluted shares outstanding should be approximately $81.1 million, exclusive of any share repurchases. Taken together, we expect our Q1 diluted EPS to be in the range of $0.37 to $0.40.
我們的有效稅率應約為25%,稀釋後流通在外股數應約為8,110萬股(不含任何股票回購)。綜合以上,我們預期第一季稀釋後每股盈餘介於0.37至0.40美元。
Let me now provide some directional comments with respect to the full year 2016. From a total revenue standpoint, we anticipate year-over-year growth to be in the low to mid 20s% and somewhere in the upper half of our long-term operating model. From a volume perspective, we expect continued strong growth in Invisalign case shipments. For scanners, based on current backlog and demand for our new iTero Element, we expect scanner revenue to be approximately double that of 2015.
現在讓我就2016年全年提供一些方向性的評論。從總營收的角度來看,我們預期年對年成長將落在低到中段的20%區間,並且位於我們長期營運模型的上半部。從出貨量的角度來看,我們預期Invisalign病例出貨將持續強勁成長。至於掃描器,基於目前的積壓訂單以及市場對我們新款iTero Element的需求,我們預期掃描器營收約為2015年的兩倍。
Notwithstanding higher top-line growth in 2016, we believe 2016 operating margins will be relatively consistent with our 2015 results for the following reasons. First of all, 2016 will bear the full year impact of the additional aligner policy, which we anticipate will impact revenues by approximately $25 million to $30 million. Secondly, we anticipate higher overall mix of iTero scanner revenue in 2016. And while the new iTero Element scanner is more profitable than the older version, it still carries lower gross margins than Invisalign clear aligners and, therefore, will somewhat dampen total margins.
儘管2016年營收成長較高,我們認為2016年的營業利益率將與2015年的結果大致一致,原因如下。首先,2016年將承擔「額外牙套政策」的全年影響,我們預期這將使營收減少約2,500萬至3,000萬美元。其次,我們預期2016年iTero掃描器營收占比將提高。雖然新款iTero Element掃描器的獲利能力高於舊款,但其毛利率仍低於Invisalign透明牙套,因此將在一定程度上拉低整體毛利率。
Finally, while we expect to complete most of the implementation of our new ERP system by midyear, the smaller percentage of these program costs can be capitalized in these later stages, meaning more of these costs will now be included in operating expense.
最後,雖然我們預期在年中前完成新ERP系統的大部分導入,但在這些後期階段,可資本化的專案成本比例較小,意味著更多成本將改列入營業費用。
For the full year, we expect ERP implementation expenses to be relatively consistent with 2015. We believe these investments are key to continued customer adoption and accelerating our growth. Similar to last year, many of these investments will take time before they realize meaningful returns. All included, we expect our earnings power in the second half of the year to be stronger than the first half with second-half operating profits to account for somewhere in the range of 55% to 60% of our full-year results.
就全年而言,我們預期ERP導入費用將與2015年大致一致。我們相信這些投資是推動客戶持續採用並加速成長的關鍵。與去年類似,許多投資需要時間才能帶來顯著回報。綜合而言,我們預期下半年獲利能力將強於上半年,下半年營業利益約占全年結果的55%至60%。
With that, I will turn the time back over to Joe for final comments. Joe?
接下來,我把時間交回給Joe做最後的評論。Joe?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Thanks, David. As you have seen from our record 2015 results, the investments we made in the onset of the year have helped us accelerate growth and increase adoption of Invisalign globally. These results reaffirm our confidence in and commitment to new investments in 2016. This year, we will continue to invest in international expansion in new country markets like India and Korea, sales in customer support resources, as well as product and technology innovation to address such things as treatment times, indication unique to teens and predictability.
謝謝,David。從我們創紀錄的2015年成果可以看出,我們在年初所做的投資,已協助我們加速成長並提升Invisalign在全球的採用率。這些成果再次強化我們對2016年新增投資的信心與承諾。今年,我們將持續投資於國際擴張,進入如印度與韓國等新國家市場;也會投入銷售與客戶支援資源,以及產品與技術創新,以改善例如療程時間、青少年專屬適應症與可預測性等面向。
In addition, we will establish our first order acquisition and treatment planning facilities in international regions so we can be closer to our customers, improve our operational efficiency, and provide doctors with the great experience to further improve their confidence in using Invisalign to treat more patients, more often. All told, we believe these investments will further extend our competitive advantage and leadership in the market.
此外,我們將在國際區域設立第一個接單取得與治療規劃設施,以便更貼近客戶、提升營運效率,並為醫師提供更佳體驗,進一步提升他們使用Invisalign治療更多患者、且更頻繁使用的信心。總體而言,我們相信這些投資將進一步擴大我們的競爭優勢與市場領導地位。
Thank you for your time today. I look forward to sharing more details with you as the year unfolds. I will now open the call to your questions. Operator?
感謝各位今天撥冗參與。隨著今年進展,我期待與各位分享更多細節。現在我將開放電話會議進入提問。接線員?
Operator
Operator
(Operator Instructions) Robert Jones, Goldman Sachs.
(接線員指示) Robert Jones,高盛。
Robert Jones - Analyst
Robert Jones - Analyst
On the revenue outlook for the year, based on the full-year outlook and the doubling of the scanners, it looks like you are implying high teens Invisalign revenue growth. I was just hoping maybe you can share a little bit more around the assumptions behind that, both from a volume versus pricing perspective. And then, if you could, share anything on geographically how you are thinking about the year, specifically curious about APAC, just given some of the concerns out there and the strong growth you have seen. Just anything you can share behind the what seems to be very healthy Invisalign revenue growth would be helpful.
就今年的營收展望而言,根據全年指引以及掃描器營收倍增來看,似乎意味著Invisalign營收成長落在十幾%的高段。我想請你們多分享一些背後的假設,包含出貨量與定價各自的影響。另外,如果可以的話,也請分享你們對各地區的看法,特別是亞太地區(APAC),考量到外界的一些疑慮以及你們所看到的強勁成長。任何能補充說明、看起來相當健康的Invisalign營收成長背後因素,都會很有幫助。
David White - CFO
David White - CFO
I will give you a couple of pieces. Let me kind of start with the scanners since that is where you started from. We announced the iTero Element scanner back in March of last year and really only began shipping that product back in September. And during that interim period, we were actively promoting the product and selling it and generating interest at all kinds of conferences and so forth and taking orders for the product at that point in time.
我提供幾點說明。先從你提到的掃描器開始。我們在去年3月發布iTero Element掃描器,實際上直到9月才開始出貨。在這段期間,我們積極推廣並銷售該產品,在各類會議等場合引發市場興趣,並在當時開始接受訂單。
And so since September, December, which we just began shipping that product, we have accumulated some backlog, and we have shipped what we had supply capabilities of. And we are starting the year with a very healthy demand profile for the product that is really driving the comment I made about we are expecting that revenue to double year over year. We wouldn't expect it to double in 2017, although we would love to have that high quality problem. But that is kind of how we are looking at 2016 as it relates to the scanner business.
因此,自9月到12月(我們剛開始出貨該產品的期間),我們累積了一些積壓訂單,而我們也在供應能力允許的範圍內進行出貨。我們以非常健康的需求態勢開啟今年,這正是我提到我們預期該項營收將年對年倍增的原因。我們不預期2017年還會再倍增,雖然我們很樂意遇到那樣的高品質煩惱。這就是我們對2016年掃描器業務的看法。
When you look at the clear aligner business, the only color I will give you as it relates to volumes and so forth is that you can see by the slides and our commentary and so forth, our international business is growing at a faster rate than what North America is, notwithstanding the fact that we have had a great rebound in North America. Our EMEA business is growing in 2015, grew roughly at the same rate as APAC did, although a few points behind but pretty close. And we expect to continue to see strong growth in each of those international regions as we continue to make investments in expanding our territory coverage. And, as Joe mentioned in his comments, actually entering into some new geographies.
至於透明牙套業務,關於出貨量等面向我能提供的補充是:從投影片與我們的評論可以看到,儘管北美市場強勁反彈,我們的國際業務成長速度仍快於北美。我們的EMEA業務在2015年的成長率大致與APAC相當,雖然略低幾個百分點,但非常接近。隨著我們持續投資擴大區域覆蓋,我們預期各個國際區域都將持續呈現強勁成長。而且,如Joe在評論中提到的,我們也會實際進入一些新的地理市場。
When you look at North America, like I said, we had a great rebound. We're expecting that to continue. We have continued to add territory coverage here in the US. And we have seen the results, I think, of some of that manifest in not only volumes, but higher utilization rates in both channels in North America. So when you net all that together, we are seeing 2016 from a revenue standpoint being somewhere, as I indicated, the growth being in the mid to low 20s%. And I don't know if that gives you enough color there or not.
再看北美,如我所說,我們出現了很好的反彈。我們預期這樣的趨勢將持續。我們在美國持續增加區域覆蓋。我認為我們已看到部分成果反映在不僅是出貨量,還包括北美兩個通路的使用率提升。因此綜合以上,我們對2016年營收的看法是,如我所指出的,成長率將落在中到低段的20%區間。我不確定這樣的補充是否已提供你足夠的資訊。
Robert Jones - Analyst
Robert Jones - Analyst
No, no, that's helpful. Just to move away from revenue, it seems like obviously there is a lot of momentum there. But in the operating profit side, if I look at the 1Q guidance and then the outlook, even with the second half operating profits to account for 55% to 60%, it still seems like even with that back half ramp, you are expecting the year to be below those three- to five-year long-term targets.
不,不,這很有幫助。先把焦點從營收移開,顯然那邊動能很強。但在營業利益方面,如果我看第一季指引以及全年展望,即使下半年營業利益占比達55%到60%,看起來即便有下半年加速,你們仍預期全年會低於三到五年長期目標。
So either one of you, but maybe Joe, curious now that you have had a little more time with the business, is that 25% to 30% operating profit margin range, is that still the right metric to represent the profit profile for the Company, or is it something different, in your mind?
所以想請兩位其中一位回答,或許Joe更合適:在你對業務有更多時間了解之後,你認為25%到30%的營業利益率區間,仍然是代表公司獲利輪廓的正確指標嗎?還是你心中有不同的看法?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
I think it is still the right profile. If you take our end of the year operating profit you add for additional aligners and you add for FX, we are right at the bottom part of that range right now. So I mean I don't see any reason to change it at all.
我認為那仍是正確的輪廓。如果你以我們年底的營業利益為基礎,再把額外牙套的影響加回去,並把匯率(FX)的影響加回去,我們目前正好落在該區間的下緣。所以我看不出有任何理由要改變它。
Operator
Operator
Jon Block, Stifel.
Jon Block,Stifel。
Jon Block - Analyst
Jon Block - Analyst
One really high-level one, maybe for you, Joe, and then some specific annoying ones for David on the guide. So Joe, it is going to sound like a little bit of a suck up question, but, really, you have got a base that is maybe 3X what it was back in 2007. You have got a product that is really not recurring, and yet you are recapturing the growth rate. And so can you just talk to us at a high level, what is allowing you to recapture this level of maybe 20%-plus clear aligner growth, and then how many more investments do you need to layer on from, call it, exiting 2016 from that level if you would going forward?
先來一個比較高層次的問題,可能給你,Joe,然後再來幾個針對指引、比較刁鑽的具體問題給 David。所以 Joe,這聽起來可能有點像拍馬屁的問題,但確實,你們的基礎規模大概是 2007 年時的 3 倍。你們的產品其實並不是經常性收入,但你們卻又重新抓回了成長率。所以你能否從高層次談談,是什麼讓你們能重新抓回這種大約 20% 以上的透明矯正器成長?另外,從 2016 年底那個水準往前看,你們還需要再疊加多少投資?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
I would just say the growth is deep and wide in a broad sense. So if you look at our utilization levels across the board, you see them going up even in GP and ortho, substantially.
我只能說,從廣義來看,成長既深且廣。所以如果你看我們各項的使用率水準,你會看到它們全面上升,即使在一般牙醫(GP)和齒顎矯正(ortho)領域也是顯著上升。
Secondly, from a breadth standpoint, where you look internationally, the growth from an international standpoint, it is in new markets, but also there is some depth in new markets, too, like we are seeing in Spain and with TFM and things we have talked to you about before.
第二,從廣度來看,若看國際市場的成長,一方面是在新市場,但新市場也有一定的深度,例如我們在西班牙、以及 TFM 等方面看到的情況,這些我們之前也跟你談過。
I think there is also -- there is an adoption profile for plastic aligners versus metals and brackets that is starting to be accepted on a wider sense, and there is a lot more confidence out there in the sense of the use for it. I mean we see that in our discussions with orthodontists and doctors around the world, too, and people that have been with us for 11 years and people that have been with us for three or four.
我認為另外還有一點——相較於金屬矯正器與托槽,塑膠牙套的採用曲線正在被更廣泛地接受,而且市場對其使用的信心也更強。我的意思是,我們在與全球各地的矯正醫師與牙醫的討論中也看到這點;不論是跟我們合作 11 年的人,或是合作三、四年的人。
If I go off and I talk about the investment aspects, I mean, this is -- it is a high-growth business. It requires continuing investments in order to do that. I think a lot of what you have seen, Jon, we are doing this from a nondilutive standpoint if you take out an additional aligner policy and you pull away some of the ERP. But these are investments. You take a look at the ERP, we need that. I can't tell you how much this business needs an ERP platform in order to grow in the future. We basically juggle this business on Excel spreadsheets in a way that is just not a good long-term way to conduct this business. There are so many things we do that are a lot of arms and legs around here that we should be used for really interpreting information rather than generating it at times. I could go on and on about that.
如果我談到投資面向,我的意思是——這是一個高成長的業務。要做到這點,就需要持續投資。Jon,我想你看到的很多作法,若把額外矯正器方案(additional aligner policy)以及部分 ERP 的影響拿掉,我們是以不稀釋(nondilutive)的方式在做。但這些仍然是投資。你看看 ERP,我們需要它。我無法跟你說這個業務未來要成長有多需要一個 ERP 平台。我們基本上是用 Excel 試算表在「勉強」運作這個業務,這絕對不是長期經營的好方式。我們有太多事情是靠很多人力在撐;我們更應該把人力用在解讀資訊,而不是有時候用在產生資訊。我可以一直講下去。
Secondly, to go into Korea, to go into Taiwan, to move into India, those aren't just salespeople. There is certain infrastructure, certain compliance, certain things that you just need to invest in to ensure that you adequately go into those markets, and we will continue to do that. But hopefully, Jon, and you know us well, you see that we are doing that in a sense of not telling you to hang on for three years. We are getting good returns on those investments, and what David and I are projecting right now, we will see the same thing in 2016.
第二,進入韓國、進入台灣、再往印度推進,那些不只是多請幾個業務。你需要一定的基礎建設、一定的法規遵循、以及一些你必須投資的事項,才能確保你能妥善進入那些市場;我們也會持續這麼做。但希望你也了解,Jon,你很了解我們,你會看到我們不是在跟你說「再忍三年」。我們在這些投資上取得了不錯的回報,而 David 和我目前的預期是,2016 年也會看到同樣的情況。
Jon Block - Analyst
Jon Block - Analyst
Okay. That was very helpful. And then, it dovetails well into the next question for you, David, or just sort of three quick little parts. You mentioned flat operations margins year over year, but I do think you have roughly an additional or an incremental 12 or 13 from the additional aligner program -- full year versus six months. So should I think about it on a non-GAAP basis the operations margins are up maybe roughly 100 bps year over year? And then you mentioned the ERP expense. What is that that is similar to 2015? And then, finally, just the tax rate -- R&D tax credit, it looks like we have going forward, so does the tax rate going forward look like it was for full-year 2015? Thanks, guys.
好的。這非常有幫助。接著也很順地帶到下一個問題給你,David,或說三個很快的小部分。你提到營運利潤率年對年持平,但我認為你們大概有額外矯正器方案帶來的約 12 或 13(的增量)——全年相較於只有六個月。所以我是否可以這樣想:在非 GAAP 基礎下,營運利潤率年對年大概提升約 100 個基點?然後你提到 ERP 費用。那部分跟 2015 年相近的是多少?最後是稅率——研發稅額抵減看起來我們未來會有,那麼未來的稅率看起來會像 2015 全年的水準嗎?謝謝各位。
David White - CFO
David White - CFO
So flat on the operating margins and your question in that regard. If you look, again, back to what Joe just iterated, if you pull out FX, you pull out clear aligner and you pull out the portion of ERP that we would not expect to be recurring on a long-term basis, we are in the range of our long-term model. When we gave guidance for 2015 you will recall a year ago, we were facing a lot of FX headwinds at that point in time, and we articulated that our strategy was that we would grow our way out of the FX challenge. And I think if you look at our results this last year, we largely succeeded in reclaiming a lot of that headwind.
關於營運利潤率持平以及你在這方面的問題。如果你回頭看 Joe 剛才重申的內容,若把匯率(FX)影響拿掉、把透明矯正器(clear aligner)拿掉、再把我們預期長期不會經常性發生的那部分 ERP 拿掉,我們其實落在長期模型的區間內。你會記得我們在一年前給 2015 年指引時,當時面臨很大的匯率逆風,我們也說明了策略是要用成長來走出匯率挑戰。我想如果你看我們去年這一年的結果,我們在很大程度上成功收復了不少逆風。
Now, since then, the dollars continued to strengthen, so we are still chasing a little bit of it. So we are not anticipating this to be as big of an impact in 2016 as what it was in 2015. But if I neutralize for that, we are inside the long-term model, and it is a modest improvement, as you articulated, over 2015 when you look at it apples to apples.
不過,自那之後,美元持續走強,所以我們仍在追趕其中一部分影響。因此我們不預期 2016 年的影響會像 2015 年那麼大。但如果我把這些因素中和掉,我們是在長期模型之內;而且如你所說,若用同口徑(apples to apples)來看,相較 2015 年是小幅改善。
On the tax rate question you had, one of the -- our guidance for Q1 was 25% or you saw that our rate last year was 22-point-something-percent I think was the effective rate. Part of one of the things that is driving it -- in fact, probably the largest thing that is actually driving that is the growth of our scanner business. And those sales are largely being made here in the United States where they are taxed at the -- our US federal and state tax rates. And that is driving some pressure on the tax rate as it currently stands.
關於你問的稅率,我們對第一季的指引是 25%,而你也看到我們去年稅率大概是 22 點多%,我想那是有效稅率。其中一個——其實可能是最大的——驅動因素,是我們掃描儀業務的成長。而那些銷售多數是在美國完成,因此會按照美國聯邦與州的稅率課稅。這使得目前的稅率承受一些上行壓力。
So my best guidance for you at this point would be somewhere in that ballpark. I haven't got a better number than that.
所以我目前能給你的最佳指引,大概就是落在那個區間附近。我沒有比那更好的數字。
Operator
Operator
Steve Beuchaw, Morgan Stanley.
Steve Beuchaw,Morgan Stanley。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
First question is actually on Element gross margin. You mentioned that they are likely to be higher relative to the prior iteration of iTero. My sense is that what we saw in this quarter is probably not a great barometer for how high they can go as you are still (technical difficulty). Is that a fair assessment?
第一個問題其實是關於 Element 的毛利率。你提到它們相較於上一代 iTero 可能會更高。我的感覺是,我們在本季看到的數字可能不是衡量它們能到多高的好指標,因為你們仍在(技術問題)。這樣的判斷合理嗎?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
It would be, Steve. Given that we are just starting to ramp the product and so forth, we still have a learning curve that we are going down. We are still or were still experiencing a yield ramp on the product. So we are expecting it to be reasonably better in 2016 than in 2015.
合理,Steve。鑑於我們才剛開始把產品放量、等等,我們仍在走一段學習曲線。我們仍然(或當時仍在)經歷產品良率的爬坡。因此我們預期 2016 年會比 2015 年明顯更好。
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
Okay. Got it. And then, two quick ones for Joe. One is on expansion of the commercial force. Can you speak to the magnitude of ads in 2016, how they might compare to what you did in 2015, appreciating that 2015 was a big year?
好的。了解。接著給 Joe 兩個快問。第一個是關於商業團隊的擴編。你能談談 2016 年新增人數的規模,以及它們可能如何與 2015 年相比嗎?也理解 2015 年是很大的一年。
And then, normally, in January as you think about working with Align over the years, normally in January we hear a little bit about product launches, plans for innovation, it wasn't as big a focus. Could we see something interesting at, say, the AAO, or is this maybe a quieter year on the product launch front? Thanks.
接著,通常在一月,當你回顧多年來與 Align 合作的情況時,一般我們在一月會聽到一些關於產品上市、創新計畫的消息,但這次並沒有那麼成為重點。我們是否可能在例如 AAO 看到一些有趣的內容,還是說今年在產品發布方面可能會比較安靜?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Steve, first of all, from kind of a commercial investment standpoint as the basis of your question, I would say very similar to 2015, but you would say more up in international and a little bit less in North America from a ratio standpoint. I think that expansion is something we just need to do. We know we get a decent return on it, as I mentioned before, and we don't see it as being dilutive. I don't think we see it as being expansive.
Steve,首先,就你問題所依據的商業投資角度來看,我會說與 2015 年非常相似,但從比例上來看,國際市場會更高一些,而北美會少一點。我認為擴張是我們必須做的事。如我先前提到的,我們知道這能帶來不錯的回報,而且我們不認為這會造成稀釋效應。我也不認為我們把它視為大幅擴張。
And, Steve, your second question was?
另外,Steve,你的第二個問題是?
Steve Beuchaw - Analyst
Steve Beuchaw - Analyst
The question is about (technical difficulty) for product launches, innovation cadence in 2016.
問題是關於(技術困難)2016 年產品上市與創新節奏。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Yes. We will have some announcements on product launches and some things that we think will be pretty exciting for the industry. In that sense, I can't necessarily talk about that now. We are still moving through different clinicals and things that exist out there. But I think from a broader standpoint, too, Steve, not think I know, we continue to focus a huge amount on engineering. We see so many additional malocclusions that we can address through our technology, and we will continue to invest that way going forward so we can capture a larger and larger percentage of the market. But we will have some exciting announcements in 2016.
是的。我們會就產品上市做一些公告,也會有一些我們認為對產業相當令人振奮的事情。就這點而言,我現在不一定能談太多。我們仍在推進不同的臨床(試驗)以及目前在外部進行的各項工作。但從更宏觀的角度來看,Steve,不是我認為,而是我知道,我們仍持續把大量重點放在工程研發上。我們看到透過我們的技術,還有非常多額外的咬合不正類型可以處理;我們未來也會持續以這個方向投資,讓我們能夠掌握越來越高的市場占比。不過我們在 2016 年會有一些令人振奮的公告。
Operator
Operator
(Operator Instructions) John Kreger, William Blair.
(接線員指示)John Kreger,William Blair。
John Kreger - Analyst
John Kreger - Analyst
Joe, I know sometimes it can be hard for you guys to get a good market assessment, given all those share gains you have gotten, but what is your view, if you go around the horn, the US orthodontic market, GP, and then Asia and Europe, does the market feel to you like it is getting better or worse based upon feedback you are getting from your sales reps?
Joe,我知道在你們取得那麼多市占提升的情況下,有時候要做出好的市場評估可能不容易;但你怎麼看——如果我們逐一看,美國矯正市場、GP(一般牙科),以及亞洲與歐洲——根據你從業務代表那邊得到的回饋,市場給你的感覺是變好還是變差?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
John, my comment would be that it seems to be stable. I think we saw an uptick in the market in 2015, and you go through the statistics and you can see it. Fortunately, we just traveled around the world for sales kickoff meetings from North America, Pacific and also Europe. In each one of those cases, we talk about a market that is pretty much stable from year to year, in that sense. I wouldn't count on a big market uplift.
John,我的看法是,市場看起來相對穩定。我認為我們在 2015 年看到市場有些回升,你去看統計數據就能看得出來。幸運的是,我們剛完成全球的銷售啟動會議巡迴,涵蓋北美、太平洋地區以及歐洲。在每一個地區,我們談到的市場基本上都是年對年相當穩定。我不會指望市場會有大幅度的上行提升。
So what we are basically expressing here in our 2016 forecast is continued penetration in those markets.
因此,我們在 2016 年的預測中基本上表達的是:在這些市場持續提高滲透率。
John Kreger - Analyst
John Kreger - Analyst
Great. Thanks. And then, maybe just to expand a little bit more about what you are hearing out of China, given some of the headlines in that region. How comfortable are you that the really strong growth that you guys have seen in the last year can hold up as we move through 2016?
很好。謝謝。另外,或許再多談一點你們從中國那邊聽到的情況,考量到該地區的一些新聞標題。你們對於過去一年看到的非常強勁成長,在進入 2016 年後仍能維持,有多大把握?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
You know, China is really interesting in this sense. You know, we saw we doubled our growth last year. We spent a lot of focus in resources on China. The quick answer to your question is that we feel good about China growth next year. Just a week ago, we were together with that team. That team is very excited about it as we move into 2016. They are not feeling a lot of what we see and get concerned with from a Western standpoint with what is going on with the Chinese GDP figures and also some of the industrial investment that is going on there.
你知道,中國在這方面真的很有意思。你知道,我們去年成長翻倍。我們在中國投入了大量資源與重點。對你問題的簡短回答是:我們對明年中國的成長感覺良好。就在一週前,我們還和那個團隊在一起。隨著我們進入 2016 年,那個團隊對此非常興奮。他們並沒有太感受到、也沒有像我們從西方角度所看到並擔心的那樣——例如中國 GDP 數據,以及當地一些工業投資的情況。
Look, I am long enough in business to always be on my toes in this sense, that something might change, but from what we see right now and what we hear from our sales team from a customer base is we are looking for China demand volume to be equivalent to what we saw in 2015 in the sense of continued growth.
你看,我做生意夠久了,在這方面我一向保持警覺,因為情況可能會改變;但就我們目前看到的,以及我們從銷售團隊與客戶端聽到的,我們預期中國的需求量將與 2015 年相當,也就是持續成長。
John Kreger - Analyst
John Kreger - Analyst
Great. Thanks. And then, one last one. Are you seeing any uptick in electronic case receipts for clear aligners from any of your partner scanner companies, or is it pretty much all still coming in through iTero?
很好。謝謝。最後一個問題。你們是否看到來自任何合作掃描器公司的透明矯正器電子病例收件量有所增加,還是幾乎仍然全部都透過 iTero 進來?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
It is pretty much all through iTero. We are seeing a little bit right now, but we are just on the beginning edge of the qualifications of those. So specifically Serono. You know that is done. There is a qualification aspect that they are going through with their customers to make that work, but there is nothing that I would say is material and meaningful yet.
幾乎都還是透過 iTero。我們現在有看到一點點,但我們才剛開始進入對那些(合作方)的資格認證流程。具體來說是 Serono。你知道,那部分已經完成。他們正在與其客戶進行一個資格認證的環節,讓流程能運作起來,但目前還沒有我會說是具體且有意義的量。
Operator
Operator
Richard Newitter, Leerink Partners.
Richard Newitter,Leerink Partners。
Richard Newitter - Analyst
Richard Newitter - Analyst
I had two. One, first, just on the ASP. I caught some of the comments that I am not sure I heard. Can you just go over again what the mix shift was with respect -- I think you said in 4Q in particular that you had a shift towards less complicated cases. I just wondered, one, was that correct? And then, two, does that have anything to do with just the strength that we are seeing and the pickup in GP utilization? And is that that they are intending to use lower (inaudible) less complicated cases?
我有兩個問題。第一個,關於 ASP(平均售價)。我聽到了一些評論,但不確定我是否聽清楚。你能否再說一次,關於組合轉移(mix shift)是怎麼回事——我想你特別提到在第四季,你們的組合轉向較不複雜的病例。我想確認一下,第一,這樣理解對嗎?第二,這是否與我們看到的強勁表現、以及 GP 使用量回升有關?是否因為他們打算用較低(聽不清)來處理較不複雜的病例?
David White - CFO
David White - CFO
Yes, Rich. This is David. We announced back in June or July -- I can't remember a specific date on it -- a single arch option for both our Express 5 and i7 products, which is our lightest stage internationally and domestically as well as the E10 and light product, which is the 10 stage and 14 stage, respectively -- respective products. And those products have -- and part of the objective of that was to satisfy a need that doctors had in treating people who only had one arch to be treated. Historically, when doctors needed to use an Invisalign product to treat a single arch, they had to pay for the price of both.
是的,Rich。我是 David。我們在六月或七月曾經公告——我不記得確切日期——針對我們的 Express 5 與 i7 產品推出單顎(single arch)選項;這是我們在國際與美國市場最輕量級的方案,同時也包含 E10 與 light 產品,分別是 10 階段與 14 階段——對應的產品。而這些產品——其中一部分目標,是為了滿足醫師在治療只需要處理單一牙弓的患者時的需求。過去,當醫師需要用 Invisalign 產品來治療單顎時,他們必須支付雙顎的價格。
So we bundled -- we debundled that and gave them basically the option to divide a single arch. We have seen -- if you look at the growth of that product or that class of products in the fourth quarter relative to the rest of our business, they are going at roughly a 50% faster rate than our full cases. And we don't think that rate will necessarily continue, but that in and of itself drove some shift in our overall ASP mix to those lower side products and put some pressure on ASPs as a result.
因此我們把原本的綑綁拆開——我們做了去綑綁(debundle),基本上提供他們單顎的選項。我們看到——如果你看第四季該產品或該類產品相對於我們其他業務的成長,它們的成長速度大約比全口病例快 50%。我們不認為這個速度一定會持續,但就這件事本身而言,確實使我們整體 ASP 的組合轉向較低價位的產品,因而對 ASP 造成一些壓力。
Now, two things about that. One is, when we look at the data from -- the demand from that, we certainly know how many single -- we certainly know how many dual cases we were selling previously where the doctor only wanted to treat one arch. And we can look at how the adoption of that single arch product has accelerated doctors actually using the Invisalign product relative to what they were doing previously. And so we believe we have gotten a lot of incremental volume at the low end for that and so incremental income on the margin from that at the same time.
另外,關於這點有兩件事。第一,當我們看相關數據——也就是該產品帶來的需求時,我們當然知道先前我們賣了多少雙顎病例,但其實醫師只想治療單顎。我們也能觀察到,單顎產品的採用加速後,醫師實際使用 Invisalign 產品的程度,相較於他們過去的做法有所提升。因此我們相信,在低端產品上我們取得了大量的增量出貨量,同時也在毛利上帶來增量收益。
Richard Newitter - Analyst
Richard Newitter - Analyst
Got it. Very helpful. And then, Joe, just with respect to some of the investments that you were talking about, we have heard you in China and getting closer to the customer, we have heard some explanation around the initiatives there that you want to implement. Can you tell us which ones in particular are the top priority as we move into first half of this year and what kind of the payoff landscape or timeline might be for those? Thanks.
了解。非常有幫助。接著,Joe,關於你剛才提到的一些投資,我們聽到你在中國、以及更貼近客戶方面的布局,也聽到一些你想在那邊推動的計畫說明。你能否告訴我們,隨著我們進入今年上半年,哪些項目特別是最優先的,以及這些項目的回報情境或時間表大概會是什麼?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Our top focus right now is APAC. That is where we have the most diversity in the sense of a customer base and I think the most lab time lag just from a distance standpoint and with our current operations. We move over order acquisition, which is basically when someone takes an impression, we do a CT scan and then lower it to a digital file. We move that over, getting it close to the customer who will allow us to improve that part. And then we move treatment planning treatment, which I think is the biggest customer satisfier that we can move with quickly. And we will move that over to different parts of Asia as we go through 2016, and we will begin probably with EMEA, also, to begin the foundation of that.
我們目前最主要的重點是亞太(APAC)。那裡的客戶基礎在多樣性方面是最高的,而且就距離與我們現有營運而言,我認為那裡也存在最大的(交付/處理)時間落差。我們會把訂單取得(order acquisition)移轉過去,基本上就是當有人取模時,我們做 CT 掃描,然後把它轉成數位檔案。我們會把這一段移到更靠近客戶的地方,讓我們能改善這個環節。接著我們會移轉治療規劃(treatment planning),我認為這是我們能夠快速推動、且最能提升客戶滿意度的一塊。我們會在 2016 年期間把這項能力移到亞洲不同地區,同時我們也可能會先從 EMEA 開始,建立這方面的基礎。
Our resources are somewhat limited at times. So we have to get started in APAC, and we will figure out how much residual capacity we have from movement over to Europe on the treatment piece. But we will move forward with both of those.
我們的資源有時相對有限。因此我們必須先從亞太開始,並評估在治療這一塊移轉到歐洲時,我們還有多少剩餘產能。但我們會同時推進這兩項工作。
Operator
Operator
Chris Lewis, ROTH Capital Partners.
Chris Lewis,ROTH Capital Partners。
Chris Lewis - Analyst
Chris Lewis - Analyst
I wanted to start on the teen segment. You had a nice quarter there. You pointed out the continued strength in North America. Joe, I was hoping you could spend a minute or two just talking about where teen is internationally at this point, and what is the strategy there over the next, call it, one to three years to really start driving teen in international markets?
我想先從青少年(teen)市場談起。你們在那一塊本季表現不錯。你也指出北美持續強勁。Joe,我希望你能花一兩分鐘談談目前青少年市場在國際上的進展,以及未來一到三年左右的策略是什麼,好讓青少年市場在國際市場真正開始成長?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
It is a good question, Chris. I mean I will just stand on North America for a second. We saw good results this year, and even though they are good results, it is still 75% of the marketplace, and we are not even near the penetration rate that I feel our product deserves in the sense of that particular demographic. (technical difficulty)
這是個好問題,Chris。我先就北美講一下。我們今年看到不錯的成果;即便成果不錯,北美仍占整體市場的 75%,而且就該族群而言,我認為我們的產品應有的滲透率,我們離那個水準還差得很遠。(技術問題)
Chris Lewis - Analyst
Chris Lewis - Analyst
-- of the clinical confidence. I was hoping you could elaborate on that. How are the strategies you have implemented here so far progressing per your expectations, and what types of strategies are you implementing for this year to continue that?
——臨床信心。我希望你能進一步說明。你們目前在這裡已實施的策略,進展是否符合你的預期?以及今年你們會採取哪些策略來持續推動?
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
I would say, starting in Europe, it has gone really well with the TFM process that we use, which is, I think you know, is it is our focused touch point strategy that we have with customers to bring them up the learning curve as quickly as possible. If I digress one minute, if you think about what are we doing here in this business, we are taking customers from an analog process to a digital process. And, frankly, it is not easy.
我會說,從歐洲開始,我們採用的 TFM 流程進展非常順利;我想你也知道,那是我們與客戶互動的「聚焦接觸點」策略,目的是讓他們盡可能快速地爬升學習曲線。我稍微岔題一分鐘,如果你想想我們在這個業務裡做的是什麼:我們是在把客戶從類比流程帶到數位流程。坦白說,這並不容易。
I mean, if you take a E5 or E10 case, it might be easy, but as you go up the scale and you start doing different kinds of malocclusions, it gets pretty complicated. And we have to be able to work through -- get customers up that learning curve as quickly as possible in that clinical piece. But also the business piece, too, because cash flow and different things that they associate with their analog business changes pretty dramatically as you move into a digitized business, also.
我的意思是,如果是 E5 或 E10 的案例,可能很容易,但當你往更高等級走、開始處理不同類型的咬合不正(malocclusions)時,就會變得相當複雜。我們必須能夠協助——讓客戶在臨床這一塊盡可能快速地爬升學習曲線。但也包括商業面,因為當你轉向數位化業務時,現金流以及他們在類比業務中所習慣的各種事項,也會出現相當劇烈的變化。
So from a clinic -- back to the major point that you are making from a clinical piece is doctors want that confidence that they start a case that they can be confident they are going to finish it. They are not embarrassed in front of their customer. They have to call them back in a lot of times. And TFM and those kinds of processes we are putting in place and, frankly, some other things that we are working on inside the Company, we think, are going to be able to improve that clinical competence piece as we go forward.
所以從臨床——回到你提到的重點:醫師希望有那種信心,也就是他們一旦開始一個案例,就能有把握可以完成。他們不會在病患面前感到尷尬。他們不必多次把病患叫回來。而 TFM 以及我們正在導入的這類流程,坦白說,再加上公司內部正在推動的其他一些事情,我們認為將能在未來持續提升這一塊的臨床能力。
Chris Lewis - Analyst
Chris Lewis - Analyst
Appreciate it. And then, David, maybe just one more. In terms of Invisalign ASPs, you talked about that shift towards the lower end products. Just looking out in the guidance, it looks like maybe ASPs are down slightly sequentially in the first quarter. First, is that correct? And then, second, any color you can provide on just how we should think about ASPs trending throughout the year in 2016, both in North America along with international markets? Thanks.
謝謝。接著,David,可能再問一題。關於 Invisalign 的平均銷售單價(ASP),你提到產品組合往較低端產品移動。從你們的指引來看,第一季 ASP 似乎可能較前一季略降。第一,這樣理解正確嗎?第二,你能否補充一些看法,讓我們理解 2016 年整年 ASP 的走勢該如何看待,包含北美以及國際市場?謝謝。
David White - CFO
David White - CFO
So to your point on Q1 ASPs and so forth, when you look at -- as our business grows, there is a number of things that impact the ASPs, as I talked about previously, any product mix shift from full cases to light cases. Any shift from doctors that are high-volume doctors to doctors that are less volume-driven doctors can have an impact on it because of our Advantage program, which incentivized doctors to go deep into their practices.
針對你提到的第一季 ASP 等問題,當你看——隨著我們業務成長,有多項因素會影響 ASP,正如我先前提到的,例如產品組合從全套病例(full cases)轉向輕量病例(light cases)。另外,從高量醫師轉向較低量醫師也可能造成影響,因為我們的 Advantage 計畫會激勵醫師在其診所內更深入地導入(我們的產品)。
And so when we look at those influences going over into 2016, we do have a little bit of ASP pressure on Q1, not very much. Consistent with what we saw in Q4, which was I think (inaudible) I mentioned in my script. And over the course of the year, we would -- as our utilization rates go up, we would expect to see that doctor engagement create some ASP pressure as well.
因此,當我們看這些影響延續到 2016 年時,第一季確實會有一點 ASP 壓力,但不會太大。這與我們在第四季看到的情況一致,我想我在講稿裡也提到(聽不清)。而在全年過程中,隨著我們的使用率提升,我們預期醫師參與度的提升也會帶來一些 ASP 壓力。
But generally speaking, we would look at ASPs over the course of the year for other factors that we are working on that I won't go into the details on would offset some of those impacts. And so right now, I think we would continue to say holding FX aside and additional aligner policy aside and so forth, I think we would say that our ASPs would still be in the flattish type of directional indication.
但整體而言,我們看 ASP 的全年走勢時,還有其他一些我們正在推動的因素(細節我就不展開)會抵消部分影響。所以目前我認為我們仍會說:先不考慮匯率(FX)、以及額外牙套政策等因素,我們的 ASP 方向大致會維持相對持平的走勢。
Operator
Operator
Brandon Couillard, Jefferies.
Brandon Couillard,Jefferies。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
Most of my questions have been addressed, but a couple of bookkeeping items for you, David. As far as the ERP program goes, should we expect that $12 million roughly of spend that is being absorbed in the P&L to go away in 2017, and could you sort of describe some of the benefits you anticipate on the other side of this?
我大多數問題都已經被回答了,不過還有幾個帳務/會計上的問題想請教你,David。就 ERP 計畫而言,我們是否可以預期目前約 1,200 萬美元、已在損益表(P&L)中吸收的支出會在 2017 年消失?你也能否描述一下在這項計畫完成後,你們預期會有哪些效益?
David White - CFO
David White - CFO
Yes. The vast majority of that $12 million we would expect to go away in 2017. We will be -- we do have built into 2016 a portion of operating costs associated with the new platform and so forth. So you won't get all the benefit of the $12 million, but you get the vast majority of it.
是的。我們預期那 1,200 萬美元中的絕大部分會在 2017 年消失。我們——在 2016 年的規劃中,確實已納入一部分與新平台等相關的營運成本。因此你不會拿到完整的 1,200 萬美元效益,但會拿到其中的絕大部分。
In terms of benefits, there is a number of them, and I think the ones that we are probably most excited about from a business standpoint have to do with our ability to offer products and services to our customers today -- tomorrow that are very difficult for us to offer to them today because of some system limitations. And so we have a number of ideas that we have not announced at this point that we are actually working on that we hope to be able to launch not far after the date we go live on our new ERP system.
就效益而言,有好幾項;我想從業務角度我們最興奮的,可能是我們能夠向客戶提供產品與服務的能力——也就是在未來(明天)能提供一些我們今天因為系統限制而很難提供的東西。因此我們有一些目前尚未對外宣布的想法,正在實際推進中;我們希望在新 ERP 系統上線後不久,就能推出。
And so we think our doctors are going to appreciate some of those changes. We think it will drive improvements in their customer experience. We think it will allow us to get our business more closely aligned with their business model at the same time so that we practice our relationship with them more closely approximates the type of relationship they have with their patients. And I won't go into more details than that, but we think that the customer experience will be greatly enhanced.
因此,我們認為我們的醫師會欣賞其中一些變更。我們認為這將推動他們客戶體驗的改善。我們認為這也將使我們的業務能更緊密地與他們的商業模式對齊,讓我們與他們之間的合作關係更貼近他們與病患之間的關係型態。我不會再深入細節,但我們認為客戶體驗將大幅提升。
And then the other thing is from an internal standpoint, when we launch new programs here in the Company, there is a significant amount of heavy lifting that has to be done even to announce and launch a new promotion. And when you consider that we have got a number of systems that all have to be updated, they have got to be tested before we can go live on them, et cetera, we believe that having one consistent platform for the Company is going to improve our agility as a company, will allow us to be much more responsive to opportunities that we see in the marketplace, as well as our time to launch new initiatives and so forth.
另外,從內部角度來看,當我們在公司推出新方案時,即使只是宣布並推出一項新的促銷活動,也需要做大量繁重的準備工作。而當你考量到我們有多個系統都必須更新、在上線前還必須完成測試等等,我們相信為公司建立一個一致的平台將提升公司的敏捷性,使我們能更快速回應市場上看到的機會,也能縮短推出新計畫與新措施的時間等。
Brandon Couillard - Analyst
Brandon Couillard - Analyst
And then last one, can you give us a sense of what we should be embedding for the currency headwind on revenues next year and then any sense of CapEx full spend for the full year?
最後一個問題,你能否讓我們了解一下,明年營收在匯率方面的逆風應該納入多少,以及全年資本支出(CapEx)總支出大概會是多少?
David White - CFO
David White - CFO
When you say headwinds in 2016 for FX, right now we are accounting zero because we gave our guidance for the year based at today's current rates. And I don't know what their euro is at right now, but $1.08, $1.09, something like that and all the other currencies roughly at those rates.
你是指2016年外匯(FX)的逆風嗎?就目前而言,我們的假設是零,因為我們是以今天的即期匯率為基礎提供今年的指引。我不確定歐元現在是多少,但大概是1.08美元、1.09美元之類,其他貨幣也大致在那些水準。
On the CapEx side, I think our guidance for the quarter was -- is in the press release, like $20 million, $25 million. And I think for the year, it is somewhere going to be in about the $60 million range. Most of that will be spent on manufacturing capacity additions.
在資本支出方面,我想我們對本季的指引——新聞稿裡有——大約是2,000萬到2,500萬美元。而全年我想大概會在6,000萬美元左右。其中大部分將用於製造產能的擴增。
Operator
Operator
Jeff Matthews, Ram Partners.
Jeff Matthews,Ram Partners。
Jeff Matthews - Analyst
Jeff Matthews - Analyst
I have two questions. One is a follow-up on Brandon's ERP question. You don't seem to be having the cost overruns and glitches that many other companies do when they get into this. Is that accurate, and is the timetables for going live roughly the same as it was when you started?
我有兩個問題。第一個是延續Brandon關於ERP的問題。你們似乎沒有像許多其他公司在導入時那樣出現成本超支和系統故障。這樣說正確嗎?另外,上線時程是否大致與你們一開始規劃的相同?
David White - CFO
David White - CFO
So, to your first part of that question, it is -- I think for any company a change of an ERP system is a significant undertaking. We have a lot of people engaged in doing this. A lot of energy and momentum behind it. So I wouldn't say it has been easy. But we are making great progress, and when we announced the program a year ago in the same call at the end of Q4 of 2014, we expect it to be going live somewhere around midyear 2016, and we are still on that plan.
就你問題的第一部分而言——我認為對任何公司來說,更換ERP系統都是一項重大工程。我們有很多人投入其中。也投入了大量的精力與動能。所以我不會說這很容易。但我們進展非常順利;而且當我們在一年前、也就是2014年第四季結束時的同一場電話會議上宣布這個計畫時,我們預期會在2016年年中左右上線,我們目前仍按此計畫進行。
Jeff Matthews - Analyst
Jeff Matthews - Analyst
Great. Thanks. And then, what I am really interested in is India, and coming on the heels of just marking your 10th year in Japan, because I know you spend a lot of time in Japan working through case complexities before you go into China, and I am just wondering how you view the potential in India relative to what you have seen in China, and is there anything that makes long-term potential there markedly different, positively or negatively? Thanks.
很好。謝謝。接著,我真正感興趣的是印度,以及你們剛剛迎來在日本的第10年,因為我知道你們在進入中國之前,會花很多時間在日本處理各種病例的複雜性;我想請教你們如何看待印度的潛力,相較於你們在中國所看到的情況,印度的長期潛力是否有任何顯著不同之處(正面或負面)?謝謝。
Joe Hogan - President, CEO and Director
Joe Hogan - President, CEO and Director
Jeff, I have been doing business in China and India for 15, 20 years, and I think you are always in jeopardy of comparing those two markets and trying to make them similar. They are just night and day. I think India has a good opportunity for us. You can see we are going into Tier 1 kind of cities that we will start in. There is a good number of orthodontic case starts that are similar to China, but the similarity really stops there.
Jeff,我在中國和印度做生意已經15到20年了,我認為你總是很容易陷入把這兩個市場拿來比較、並試圖把它們看成相似的風險。但它們其實截然不同。我認為印度對我們而言有不錯的機會。你可以看到我們將從一線(Tier 1)城市開始進入。那裡有相當數量的正畸病例啟動量,與中國有些相似,但相似之處大致也就到此為止。
And so we expect good growth, but I don't expect a lot of what we are doing in China to be transferable to India in the sense from a commercial standpoint. And we're going to have to get into each one of those cities and learn and adapt properly as we move forward. But it is a focus for us. We're going to have to be successful there. But we are going to take it -- we're going to start one step at a time, and 2016 will be a foundational year for us.
因此我們預期會有良好的成長,但我不認為我們在中國所做的很多事情能在商業層面直接移植到印度。我們必須進入每一個城市,隨著推進不斷學習並適當調整。但這是我們的重點之一。我們必須在那裡取得成功。不過我們會——我們會一步一步來,而2016年將是我們打基礎的一年。
Shirley Stacy - VP, Corporate Communications and IR
Shirley Stacy - VP, Corporate Communications and IR
Well, thank you, everybody for joining us today. We look forward to seeing you at upcoming conferences and industry events, including the Chicago midwinter meeting at the end of February. We also hope you'll join us for our financial analyst meeting, which is scheduled for Thursday, June 2, in New York City. More details will follow, but for now please hold that date on your calendars. If you have any questions, please contact Align Investor Relations. Have a great day.
好的,感謝各位今天加入我們。我們期待在接下來的各項會議與產業活動中與各位見面,包括2月底在芝加哥舉行的冬季年會。我們也希望各位能參加我們的金融分析師會議,預定於6月2日(週四)在紐約市舉行。後續會提供更多細節,但目前請先在行事曆上預留這個日期。如有任何問題,請聯絡Align投資人關係部門。祝各位有美好的一天。
Operator
Operator
This concludes today's teleconference. You may disconnect your lines at this time, and have a wonderful rest of your day.
今天的電話會議到此結束。您現在可以掛線,祝您今天剩餘時間愉快。